Results 21 to 30 of about 180,829 (383)

Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial.

The Lancet Haematology, 2022
BACKGROUND Odronextamab is a hinge-stabilised, fully human IgG4-based CD20 × CD3 bispecific antibody that binds CD3 on T cells and CD20 on B cells. We aimed to evaluate the safety and antitumour activity of odronextamab in patients with relapsed or ...
R. Bannerji, J. Arnason, R. Advani, Jennifer R. Brown, J. Allan, S. Ansell, J. Barnes, S. O'brien, J. Chavez, J. Duell, A. Rosenwald, J. Crombie, M. Ufkin, Jingjin Li, Min Zhu, S. Ambati, A. Chaudhry, I. Lowy, M. Topp   +18 more
semanticscholar   +1 more source

Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas

Blood, 2023
Key Points • We identified CD20 loss at progression in the phase 1/2 GO29781 trial of mosunetuzumab monotherapy in B-cell NHL.• Reduced transcription or gain of truncating mutations explained most but not all cases of CD20 loss with mosunetuzumab.
S. Schuster, Ling-Yuh Huw, C. Bolen, Victor Maximov, A. Polson, Katerina Hatzi, E. A. Lasater, S. Assouline, N. L. Bartlett, L. Budde, M. Matasar, Hartmut Koeppen, E. Piccione, D. Wilson, Michael C Wei, S. Yin, E. Penuel   +16 more
semanticscholar   +1 more source

Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy

Nature Medicine, 2021
SARS-CoV-2 messenger RNA vaccination in healthy individuals generates immune protection against COVID-19. However, little is known about SARS-CoV-2 mRNA vaccine-induced responses in immunosuppressed patients. We investigated induction of antigen-specific
Sokratis A. Apostolidis, Mihir Kakara, Mark M. Painter, R. Goel, D. Mathew, Kerry Lenzi, Ayman Rezk, K. Patterson, Diego A. Espinoza, Jessy C. Kadri, Daniel M. Markowitz, Clyde E. Markowitz, Ina Mexhitaj, D. Jacobs, Allison Babb, Michael R. Betts, Eline T. Luning Prak, D. Weiskopf, A. Grifoni, Kendall A. Lundgreen, S. Gouma, Alessandro Sette, Paul Bates, S. Hensley, A. Greenplate, E. Wherry, Rui Li, Amit Bar-Or   +27 more
semanticscholar   +1 more source

Secondary hypogammaglobulinemia in patients with multiple sclerosis on anti-CD20 therapy: Pathogenesis, risk of infection, and disease management.

Multiple Sclerosis and Related Disorders, 2023
Hypogammaglobulinemia is characterized by reduced serum immunoglobulin levels. Secondary hypogammaglobulinemia is of considerable interest to the practicing physician because it is a potential complication of some medications and may predispose patients ...
E. Alvarez, E. Longbrake, K. Rammohan, James Stankiewicz, Carrie M. Hersh   +4 more
semanticscholar   +1 more source

Non-Hodgkin lymphoma of cauda equina: A diagnostic conundrum: Case report

Advanced Biomedical Research, 2023
Primary central nervous system lymphoma (PCNSL) is uncommon with scarce cases having involvement of the spinal cord. Cauda equina is unique in its location and shows very rare involvement by diseases pathologies.
Pranati Misra, Ranjita Panigrahi, Prita Pradhan, Debashis Pothal, Urmila Senapati, Narendra K Das   +5 more
doaj   +1 more source

Differential effects of anti-CD20 therapy on CD4 and CD8 T cells and implication of CD20-expressing CD8 T cells in MS disease activity

Proceedings of the National Academy of Sciences of the United States of America, 2023
Significance CD20-expressing CD4+ and CD8+ T cells harbor proinflammatory and central nervous system (CNS)-homing attributes. The inverse relationship between levels of these cells (particularly the CD20dimCD8+ T cells) in the circulation of MS patients,
Koji Shinoda, Rui Li, Ayman Rezk, Ina Mexhitaj, K. Patterson, Mihir Kakara, Leah Zuroff, J. Bennett, H.-Christian von Büdingen, R. Carruthers, K. Edwards, R. Fallis, P. Giacomini, Benjamin M. Greenberg, D. Hafler, C. Ionete, U. Kaunzner, C. Lock, E. Longbrake, G. Pardo, F. Piehl, Martin S. Weber, T. Ziemssen, D. Jacobs, J. Gelfand, A. Cross, B. Cameron, B. Musch, Ryan C Winger, Xiaoming Jia, Christopher T Harp, A. Herman, A. Bar-Or   +32 more
semanticscholar   +1 more source

Efficacy and safety of anti-CD20 monoclonal antibody therapy for autoimmune nodopathies: a systematic review and meta-analysis. [PDF]

Front Neurol
Tao Z, Jiang Y, Gui Q, Ma J.
europepmc   +3 more sources

Novel chimerized IgA CD20 antibodies: Improving neutrophil activation against CD20-positive malignancies [PDF]

mAbs, 2020
Current combination therapies elicit high response rates in B cell malignancies, often using CD20 antibodies as the backbone of therapy. However, many patients eventually relapse or develop progressive disease. Therefore, novel CD20 antibodies combining multiple effector mechanisms were generated.
Mitchell Evers, Toine Ten Broeke, J.H. Marco Jansen, Maaike Nederend, Firas Hamdan, Karli R. Reiding, Saskia Meyer, Petra Moerer, Iris Brinkman, Thies Rösner, Robert Jan Lebbink, Thomas Valerius, Jeanette H.W. Leusen   +12 more
openaire   +7 more sources

Modeling and affinity maturation of an anti-CD20 nanobody: a comprehensive in-silico investigation

Scientific Reports, 2023
B-cell Non-Hodgkin lymphomas are the malignancies of lymphocytes. CD20 is a membrane protein, which is highly expressed on the cell surface of the B-cells in NHL.
Alireza Poustforoosh, Sanaz Faramarz, M. Negahdaripour, H. Hashemipour   +3 more
semanticscholar   +1 more source

Alternative splicing of its 5′-UTR limits CD20 mRNA translation and enables resistance to CD20-directed immunotherapies

Blood, 2023
Key Points • In normal and malignant human B cells, CD20 mRNA is alternatively spliced to yield 4 5′ untranslated region isoforms, some of which are translation-deficient.• The balance between translation-deficient and -competent isoforms modulates CD20 ...
Z. Ang, L. Paruzzo, Katharina E. Hayer, Carolin Schmidt, M. Torres-Diz, Feng Xu, U. Zankharia, Yunlin Zhang, S. Soldan, Sisi Zheng, C. D. Falkenstein, J. Loftus, Scarlett Y. Yang, M. Asnani, Patricia King Sainos, Vinodh Pillai, E. Chong, Marilyn M. Li, S. Tasian, Yoseph Barash, Paul M. Lieberman, M. Ruella, S. Schuster, A. Thomas-Tikhonenko   +23 more
semanticscholar   +1 more source